bluuebunny/crossref_metadata_2025_split huggingface dataset:
Equilibrium Price Dispersion with Search Regret Disutility
Authors: Rouskas Evangelos 
Published: January 2020

I examine an extension of the Burdett and Judd ([1983] . Equilibrium price dispersion. Econometrica, 51[4], 955–970) model whereby the consumers with positive search costs experience search regret disutility. First, I focus on the non-sequential search equilibrium in which the said consumers randomize between searching for one price and searching for two prices. When the disutility is significant (a) the spectrum of parameters for which this dispersed price equilibrium can be sustained widens significantly compared to the setting with no disutility; (b) this dispersed price equilibrium is unique and stable in contrast to the multiplicity of dispersed price equilibria of this type which arise in the original model; and (c) in the stable dispersed price equilibrium of this type the consumers with positive search costs respond to the possibility of search regret disutility by increasing their equilibrium search intensity. Second, I concentrate on the noisy sequential search equilibrium in which the reservation price is endogenous. When the search cost takes relatively high values, then compared to the setting with no disutility (a) the set of parameters for which this dispersed price equilibrium is supported may become significantly smaller; (b) the reservation price decreases; and (c) the consumers with positive search costs choose the same search intensity. JEL Classifications: D41, D83
Severity of Glenohumeral Osteoarthritis Does Not Correlate With Patient-Reported Outcomes
Authors: Kohan Eitan M , Hill Jeffrey Ryan , Lamplot Joseph D , Aleem Alexander W , Keener Jay D , Chamberlain Aaron M 
Published: January 2020

Background Patient pain and clinical function are important factors in decision-making for patients with glenohumeral osteoarthritis (GHOA). The correlation between radiographic severity of arthritis and demographic factors with modern patient-reported outcome measures has not yet been well defined. Methods This cross-sectional study included 256 shoulders in 246 patients presenting with isolated GHOA. All patients obtained standard radiographs and completed the American Shoulder and Elbow Surgeons score, Simple Shoulder Test (SST), Shoulder Activity Scale, Visual Analog Scale, and Patient-Reported Outcome Measurement Information System (PROMIS) computer adaptive tests at the time of presentation. Radiographs were graded according to the Samilson–Prieto classification. Mean pain and functional scores were compared between the radiographic grades of osteoarthritis (OA) and demographic factors. Results There were 6 shoulders rated as grade 1 OA, 41 shoulders as grade 2, 149 shoulders as grade 3a, and 65 shoulders as grade 3b. There was excellent interobserver reliability in grade of OA (κ = 0.77). There were no significant differences in patient-reported pain or any validated measure of clinical function between radiographic grades of OA ( P >  .05). Males reported higher function and lower pain scores than females ( P =  .001–.066), although only the values for the SST and PROMIS physical function test were clinically relevant. Discussion While gender correlated with pain and function, the clinical relevance is limited. Radiographic severity of GHOA does not correlate with patient-reported pain and function, and symptoms should remain the primary determinants of surgical decision-making. Further investigation is necessary to examine whether radiographic severity of OA influences improvement following operative intervention in this population.
Determining the optimal human reliability analysis (HRA) method in healthcare systems using Fuzzy ANP and Fuzzy TOPSIS
Authors: Abbaspour Asghar , Saremi Mahnaz , Alibabaei Ahmad , Moghanlu Pedram S 
Published: January 2020

Purpose As one of the leading causes of deaths and injuries, medical errors constitute a veritable threat to patient safety. Despite this fact, no unique method has yet been established to identify and evaluate medical errors. This study was conducted to select an optimal human reliability analysis method compatible with healthcare systems from available methods. Design/methodology/approach: In order to select the optimal method for the identification and evaluation of medical errors, different criteria and sub-criteria were determined by reviewing the literature and based on experts’ opinions. Next, weights of criteria and sub-criteria were specified by using the fuzzy analytical network process (ANP). Finally, fuzzy technique for order preference by similarity to ideal solution method was used to prioritize the methods. Findings Six criteria and 21 sub-criteria for choosing the optimal method were determined. The utility, usability, and structure of a method had the highest influence with weights of 0.262, 0.191, and 0.187, respectively. Based on the results of fuzzy technique for order preference by similarity to ideal solution, the Human Error Assessment and Reduction Technique method with a closeness coefficient of 0.576 was selected as the optimal method for identifying medical errors. The Human Factors Analysis and Classification System and Systematic Human Error Reduction and Prediction Approach methods ranked second and third, respectively. Originality/value: To date, no studies have attempted to determine the optimal methods for identification and assessment of medical errors. This paper aimed to fill this gap by using fuzzy analytical network process and fuzzy technique for order preference by similarity to ideal solution techniques.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Authors: Carpio Cecilia , Bouabdallah Reda , Ysebaert Loïc , Sancho Juan-Manuel , Salles Gilles , Cordoba Raul , Pinto Antonio , Gharibo Mecide , Rasco Drew , Panizo Carlos , Lopez-Martin Jose A. , Santoro Armando , Salar Antonio , Damian Silvia , Martin Alejandro , Verhoef Gregor , Van den Neste Eric , Wang Maria , Couto Suzana , Carrancio Soraya , Weng Andrew , Wang Xuehai , Schmitz Frank , Wei Xin , Hege Kristen , Trotter Matthew W. B. , Risueño Alberto , Buchholz Tonia J. , Hagner Patrick R. , Gandhi Anita K. , Pourdehnad Michael , Ribrag Vincent 
Published: January 2020

Abstract
Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are limited, with no standard of care; prognosis is poor, with 4- to 6-month median survival. Avadomide (CC-122) is a cereblon-modulating agent with immunomodulatory and direct antitumor activities. This phase 1 dose-expansion study assessed safety and clinical activity of avadomide monotherapy in patients with de novo R/R DLBCL and transformed lymphoma. Additionally, a novel gene expression classifier, which identifies tumors with a high immune cell infiltration, was shown to enrich for response to avadomide in R/R DLBCL. Ninety-seven patients with R/R DLBCL, including 12 patients with transformed lymphoma, received 3 to 5 mg avadomide administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal. Eighty-two patients (85%) experienced ≥1 grade 3/4 treatment-emergent adverse events (AEs), most commonly neutropenia (51%), infections (24%), anemia (12%), and febrile neutropenia (10%). Discontinuations because of AEs occurred in 10% of patients. Introduction of an intermittent 5/7-day schedule improved tolerability and reduced frequency and severity of neutropenia, febrile neutropenia, and infections. Among 84 patients with de novo R/R DLBCL, overall response rate (ORR) was 29%, including 11% complete response (CR). Responses were cell-of-origin independent. Classifier-positive DLBCL patients (de novo) had an ORR of 44%, median progression-free survival (mPFS) of 6 months, and 16% CR vs an ORR of 19%, mPFS of 1.5 months, and 5% CR in classifier-negative patients (P = .0096). Avadomide is being evaluated in combination with other antilymphoma agents. This trial was registered at www.clinicaltrials.gov as #NCT01421524.
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Authors: Vercellino Laetitia , Cottereau Anne-Segolene , Casasnovas Olivier , Tilly Hervé , Feugier Pierre , Chartier Loic , Fruchart Christophe , Roulin Louise , Oberic Lucie , Pica Gian Matteo , Ribrag Vincent , Abraham Julie , Simon Marc , Gonzalez Hugo , Bouabdallah Reda , Fitoussi Olivier , Sebban Catherine , López-Guillermo Armando , Sanhes Laurence , Morschhauser Franck , Trotman Judith , Corront Bernadette , Choufi Bachra , Snauwaert Sylvia , Godmer Pascal , Briere Josette , Salles Gilles , Gaulard Philippe , Meignan Michel , Thieblemont Catherine 
Published: January 2020

AbstractEarly identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell–like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, &gt;1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 &gt;70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472.
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
Authors: Sanchorawala Vaishali , Sarosiek Shayna , Schulman Amanda , Mistark Meredith , Migre Mary Ellen , Cruz Ramon , Sloan J. Mark , Brauneis Dina , Shelton Anthony C. 
Published: January 2020

Abstract
Daratumumab, a monoclonal CD38 antibody, is approved in the treatment of myeloma, but its efficacy and safety in light-chain (AL) amyloidosis has not been formally studied. This prospective phase 2 trial of daratumumab monotherapy for the treatment of AL amyloidosis was designed to determine the safety, tolerability, and hematologic and clinical response. Daratumumab 16 mg/kg was administered by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxicity, for up to 24 months. Twenty-two patients with previously treated AL amyloidosis were enrolled. The majority of the patients had received high-dose melphalan and stem cell transplantation and/or treatment with a proteasome inhibitor. The median time between prior therapy and trial enrollment was 9 months (range, 1-180 months). No grade 3-4 infusion-related reactions occurred. The most common grade ≥3 adverse events included respiratory infections (n = 4; 18%) and atrial fibrillation (n = 4, 18%). Hematologic complete and very-good-partial response occurred in 86% of patients. The median time to first and best hematologic response was 4 weeks and 3 months, respectively. Renal response occurred in 10 of 15 patients (67%) with renal involvement and cardiac response occurred in 7 of 14 patients (50%) with cardiac involvement. In summary, daratumumab is well tolerated in patients with relapsed AL amyloidosis and leads to rapid and deep hematologic responses and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT02841033.
Utility of serum free light chain ratio in response definition in patients with multiple myeloma
Authors: Abdallah Nadine , Kapoor Prashant , Murray David L. , Buadi Francis K. , Dingli David , Dispenzieri Angela , Gertz Morie A. , Go Ronald S. , Gonsalves Wilson I. , Hayman Suzanne R. , Kourelis Taxiarchis V. , Lacy Martha Q. , Leung Nelson , Lust John A. , Muchtar Eli , Warsame Rahma , Kyle Robert A. , Rajkumar S. Vincent , Kumar Shaji K. 
Published: January 2020

Key PointsPatients with an abnormal sFLC ratio because of LC suppression have outcomes similar to those with a normal ratio. sFLC ratio has prognostic value in patients achieving CR who have an absence of clonal BMPCs assessed by MFC.
Comparative genomics of multidrug-resistant Enterococcus spp. isolated from wastewater treatment plants
Authors: Sanderson Haley , Ortega-Polo Rodrigo , Zaheer Rahat , Goji Noriko , Amoako Kingsley K. , Brown R. Stephen , Majury Anna , Liss Steven N. , McAllister Tim A. 
Published: January 2020

Abstract
Background
Wastewater treatment plants (WWTPs) are considered hotspots for the environmental dissemination of antimicrobial resistance (AMR) determinants. Vancomycin-Resistant Enterococcus (VRE) are candidates for gauging the degree of AMR bacteria in wastewater. Enterococcus faecalis and Enterococcus faecium are recognized indicators of fecal contamination in water. Comparative genomics of enterococci isolated from conventional activated sludge (CAS) and biological aerated filter (BAF) WWTPs was conducted.

Results
VRE isolates, including E. faecalis (n = 24), E. faecium (n = 11), E. casseliflavus (n = 2) and E. gallinarum (n = 2) were selected for sequencing based on WWTP source, species and AMR phenotype. The pangenomes of E. faecium and E. faecalis were both open. The genomic fraction related to the mobilome was positively correlated with genome size in E. faecium (p < 0.001) and E. faecalis (p < 0.001) and with the number of AMR genes in E. faecium (p = 0.005). Genes conferring vancomycin resistance, including vanA and vanM (E. faecium), vanG (E. faecalis), and vanC (E. casseliflavus/E. gallinarum), were detected in 20 genomes. The most prominent functional AMR genes were efflux pumps and transporters. A minimum of 16, 6, 5 and 3 virulence genes were detected in E. faecium, E. faecalis, E. casseliflavus and E. gallinarum, respectively. Virulence genes were more common in E. faecalis and E. faecium, than E. casseliflavus and E. gallinarum. A number of mobile genetic elements were shared among species. Functional CRISPR/Cas arrays were detected in 13 E. faecalis genomes, with all but one also containing a prophage. The lack of a functional CRISPR/Cas arrays was associated with multi-drug resistance in E. faecium. Phylogenetic analysis demonstrated differential clustering of isolates based on original source but not WWTP. Genes related to phage and CRISPR/Cas arrays could potentially serve as environmental biomarkers.

Conclusions
There was no discernible difference between enterococcal genomes from the CAS and BAF WWTPs. E. faecalis and E. faecium have smaller genomes and harbor more virulence, AMR, and mobile genetic elements than other Enterococcus spp.
Efficiency as a determinant of loyalty among users of a Community of Clinical Practice: a comparative study between the implementation and consolidation phases
Authors: Lacasta Tintorer David , Manresa Domínguez Josep Maria , Jiménez-Zarco Ana , Rodríguez-Blanco Teresa , Flayeh Beneyto Souhel , Torán-Monserrat Pere , Mundet Tuduri Xavier , Saigí-Rubió Francesc 
Published: January 2020

Abstract
Background
A community of clinical practice called the Online Communication Tool between Primary and Hospital Care (ECOPIH) was created to enable primary care and specialist care professionals to communicate with each other in order to resolve real clinical cases, thereby improving communication and coordination between care levels. The present work seeks to analyse whether ECOPIH makes it possible to reduce the number of referrals. To that end, the objectives are: (1) To find out the degree of loyalty among ECOPIH users, by comparing the medical professionals’ profiles in the tool’s implementation phase to those in its consolidation phase. (2) To evaluate the degree of fulfilment of users’ expectations, by establishing the determining factors that had an influence on the physicians’ intention to use ECOPIH in the implementation phase and observing whether its use had an effective, direct impact on the number of patient referrals that primary care physicians made to specialist care professionals.

Methods
Two studies were conducted. Based on a survey of all the physicians in a Primary Care area, Study 1 was a descriptive study in ECOPIH’s implementation phase. Study 2 was a randomised intervention study of ECOPIH users in the tool’s consolidation phase. The results from both studies were compared. Various bivariate and multivariate statistical techniques (exploratory factor analysis, cluster analysis, logistic regression analysis and ANOVA) were used in both studies, which were conducted on a sample of 111 and 178 physicians, respectively.

Results
We confirmed the existence of an ECOPIH user profile stable across both phases: under-50-year-old women. Regarding the second objective, there were two particular findings. First, the discriminant factors that had an influence on greater ECOPIH use were habitual Social media website and app use and Perceived usefulness for reducing costs. Second, PC professionals who were ECOPIH members made fewer referrals to SC professionals in Cardiology, Endocrinology and Gastroenterology than older PC professionals who were not ECOPIH members.

Conclusions
The use of a community of clinical practice by primary care and specialist care professionals helps to reduce the number of referrals among medical professionals.
Current status of integrating oncology and palliative care in Japan: a nationwide survey
Authors: Uneno Y. , Sato K. , Morita T. , Nishimura M. , Ito S. , Mori M. , Shimizu C. , Horie Y. , Hirakawa M. , Nakajima T. E. , Tsuneto S. , Muto M. 
Published: January 2020

Abstract
Background
Palliative care (PC) is increasingly recognized as essential for oncology care, and several academic societies strongly recommend integrating oncology and palliative care (IOP) in daily practice. Similarly, the Japanese government encouraged the implementation of IOP through the Cancer Control Act of 2007; however, its detailed progress remains unclear. Therefore, this cross-sectional nationwide survey was conducted to investigate the current status and hospital executive physicians’ perception of IOP.

Methods
The questionnaire was developed based on IOP indicators with international consensus. It was distributed to executive physicians at all government-designated cancer hospitals (DCHs, n = 399) and matched non-DCHs (n = 478) in November 2017 and the results were compared.

Results
In total, 269 (67.4%) DCHs and 259 (54.2%) non-DCHs responded. The number of PC resources in DCHs was significantly higher than those in non-DCHs (e.g., full-time PC physicians and nurses, 52.8% vs. 14.0%, p < 0.001; availability of outpatient PC service ≥3 days per week, 47.6% vs. 20.7%, p < 0.001). Routine symptom screening was more frequently performed in DCHs than in non-DCHs (65.1% vs. 34.7%, p < 0.001). Automatic trigger for PC referral availability was limited (e.g., referral using time trigger, 14.9% vs. 15.3%, p = 0.700). Education and research opportunities were seriously limited in both types of hospitals. Most executive physicians regarded IOP as beneficial for their patients (95.9% vs. 94.7%, p = 0.163) and were willing to facilitate an early referral to PC services (54.7% vs. 60.0%, p < 0.569); however, the majority faced challenges to increase the number of full-time PC staff, and < 30% were planning to increase the staff members.

Conclusions
This survey highlighted a considerable number of IOP indicators met, particularly in DCHs probably due to the government policy. Further efforts are needed to address the serious research/educational gaps.
The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial
Authors: Haidari Fatemeh , Banaei-Jahromi Nasrin , Zakerkish Mehrnoosh , Ahmadi Kambiz 
Published: January 2020

AbstractBackgroundPolycystic Ovary Syndrome (PCOS) is known as the most common endocrine disorder of women in reproductive ages. With the increasing prevalence of PCOS in different countries, the use of herbal medicine as an alternative treatment is growing in these patients. This study aimed to evaluate the effects of flaxseed powder supplementation on metabolic biomarkers of patients with PCOS.MethodsThis randomized open-labeled controlled clinical trial was conducted on 41 patients with PCOS. The participants were randomized to take either flaxseed powder (30 g/day) plus lifestyle modification or only lifestyle modification for 12 weeks. Anthropometric and biochemical evaluations were performed for all patients at the beginning and end of the study.ResultsThe flaxseed group showed a significant reduction in body weight, insulin concentration, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Triglycerides (TG), high-sensitivity C-Reactive Protein (hs-CRP), and leptin and an increase in Quantitative Insulin-Sensitivity Check Index (QUICKI), High Density Lipoprotein (HDL), and adiponectin compared to the baseline (p < 0.05). Flaxseed supplementation also led to a significant reduction in insulin concentration, HOMA-IR, TG, hs-CRP, Interleukin 6 (IL- 6), and leptin and an increase in QUICKI, HDL, and adiponectin compared to the control group (p < 0.05). No significant changes were observed in other parameters.ConclusionsFlaxseed supplementation plus lifestyle modification was more effective compared to lifestyle modification alone in biochemical and anthropometric variables in patients with PCOS.Trial registrationThe trial protocol was approved by the Ethics Board at Ahvaz Jundishapur University of Medical Sciences and was registered at Iranian Registry of Clinical Trials (code:IRCT20120704010181N11).
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Authors: Zhong Xiaoming , Zhang Hangtian , Zhu Ying , Liang Yuqing , Yuan Zhuolin , Li Jiachen , Li Jing , Li Xin , Jia Yifan , He Tian , Zhu Jiangyuan , Sun Yu , Jiang Wengting , Zhang Hui , Wang Cheng , Ke Zunfu 
Published: January 2020

AbstractCancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs.